Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04241185
Other study ID # 3475-992
Secondary ID MK-3475-99220538
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 19, 2020
Est. completion date June 10, 2031

Study information

Verified date May 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Email Trialsites@merck.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.


Recruitment information / eligibility

Status Recruiting
Enrollment 636
Est. completion date June 10, 2031
Est. primary completion date June 10, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has a histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology - Has clinically nonmetastatic bladder cancer (N0M0) - Has planned and is eligible to receive chemoradiotherapy (CRT) and one of the protocol-specified radiosensitizing chemotherapy regimens - Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Demonstrates adequate organ function - Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of CRT treatment: - Refrain from donating sperm - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception unless confirmed to be azoospermic - A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: - Is not a woman of childbearing potential (WOCBP) - Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 180 days the time needed to eliminate each study intervention after the last dose of study intervention; and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: MK-3475 - 120 days and CRT - 180 days Exclusion Criteria: - Has the presence of diffuse carcinoma in situ (CIS) (multiple foci of CIS) throughout the bladder - Has the presence of urothelial carcinoma (UC) at any site outside of the urinary bladder in the previous 2 years except for Ta stage/T1 stage/CIS of the upper tract if the participant has undergone a complete nephroureterectomy - Has a known additional malignancy that is progressing or has required active therapy within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or other carcinoma in situ that has undergone potentially curative therapy - Has the presence of bilateral hydronephrosis - Has limited bladder function with frequency of small amounts of urine (< 30 mL), urinary incontinence, or requires self-catheterization or a permanent indwelling catheter - Has received prior pelvic/local radiation therapy or any antineoplastic treatment for muscle-invasive bladder cancer (MIBC). Treatment for non-muscle invasive bladder cancer (NMIBC) with intravesical instillation therapy that was completed =28 days prior to randomization is allowed. Prior systemic treatment of NMIBC is not permitted. - Received prior therapy with an anti-PD-1 (programmed cell death protein 1), anti-PD-L1 (programmed death-ligand 1), or anti-PD-L2 (programmed cell death 1 ligand 2), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4 [cytotoxic T-lymphocyte-associated protein 4], OX 40, or CD137 [cluster of differentiation 137]) - Has received a live vaccine within 30 days before the first dose of study medication - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study medication - Has known severe hypersensitivity (=Grade 3) to the selected chemotherapy regimen, and/or any of their excipients and excipients of pembrolizumab - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication - Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed - Has a history of non-infectious pneumonitis that required steroids or has current pneumonitis - Has an active infection requiring systemic therapy - Has a known history of human immunodeficiency virus (HIV) infection - Has a known history of hepatitis B or known active hepatitis C virus infection - Has a known history of active tuberculosis (TB; Bacillus tuberculosis) - Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study - Has had an allogenic tissue/solid organ transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
Radiation:
Conventional Radiotherapy (Bladder only)
64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
Conventional Radiotherapy (Bladder and pelvic nodes)
64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
Hypofractionated Radiotherapy (Bladder only)
55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
Drug:
Cisplatin
35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Fluorouracil (5-FU)
5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Mitomycin C (MMC)
MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Gemcitabine
Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Placebo to Pembrolizumab
Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.

Locations

Country Name City State
Australia Monash Medical Centre ( Site 0216) Clayton Victoria
Australia Austin Health ( Site 0218) Heidelberg Victoria
Australia Liverpool Hospital ( Site 0220) Liverpool New South Wales
Australia Sir Charles Gairdner Hospital ( Site 0223) Nedlands Western Australia
Australia GenesisCare North Shore ( Site 0217) St Leonards New South Wales
Chile Bradford Hill Norte ( Site 7052) Antofagasta
Chile Bradfordhill-Clinical Area ( Site 7051) Santiago Region M. De Santiago
Chile FALP ( Site 7056) Santiago Region M. De Santiago
Chile Oncocentro Valdivia ( Site 7055) Valdivia Los Rios
Chile ONCOCENTRO APYS-ACEREY ( Site 7054) Viña del Mar Valparaiso
Czechia Fakultni nemocnice Olomouc ( Site 0559) Olomouc
Czechia 2. LF UK a FN Motol ( Site 0555) Praha 5
Czechia Nemocnice Na Bulovce ( Site 0556) Praha 8
Denmark Herlev og Gentofte Hospital. ( Site 0401) Herlev Hovedstaden
Denmark Odense Universitetshospital ( Site 0403) Odense Syddanmark
Estonia North Estonia Medical Centre Foundation ( Site 0081) Tallin Harjumaa
Estonia Tartu University Hospital ( Site 0079) Tartu Tartumaa
France CHU Amiens Picardie Site Sud Amiens ( Site 0123) Amiens Somme
France Institut Sainte Catherine ( Site 0121) Avignon Provence-Alpes-Cote-d Azur
France A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 0115) Paris
France Institut Curie ( Site 0112) Paris
Guatemala Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0146) Guatemala
Guatemala Grupo Medico Angeles ( Site 0143) Guatemala
Guatemala Medi-K Cayala ( Site 0142) Guatemala
Guatemala Oncomedica ( Site 0145) Guatemala
Guatemala Centro Medico Integral De Cancerología (CEMIC) ( Site 0144) Quetzaltenango
Hungary Debreceni Egyetem Klinikai Kozpont ( Site 0097) Debrecen
Hungary Petz Aladar Megyei Oktato Korhaz ( Site 0099) Gyor Gyor-Moson-Sopron
Hungary Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0091) Kaposvar
Hungary Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0095) Kecskemét Bacs-Kiskun
Hungary BAZ Megyei Korhaz. Klinikai Onkologia es Sugarterapias Centrum ( Site 0092) Miskolc Borsod-Abauj-Zemplen
Israel Soroka Medical Center-Oncology ( Site 7031) Be'er Sheva
Israel Rambam Health Care Campus-Oncology Division ( Site 0088) Haifa
Israel Hadassah Medical Center. Ein Kerem ( Site 0086) Jerusalem
Israel Rabin Medical Center ( Site 7032) Petah Tikva
Israel Chaim Sheba Medical Center ( Site 0087) Ramat Gan
Israel Sourasky Medical Center ( Site 0089) Tel Aviv
Italy IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0193) Bari Puglia
Italy AOU Careggi ( Site 0191) Firenze
Italy Ospedale Civile di Macerata ( Site 0190) Macerata
Italy Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0186) Milano
Italy Ospedale San Raffaele ( Site 0194) Milano Lombardia
Italy Azienda Ospedaliero - Universitaria Policlinico di Modena ( Site 0188) Modena
Italy Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0192) Napoli
Italy Fondazione Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 7041) Roma Lazio
Japan Hirosaki University Hospital ( Site 0602) Hirosaki Aomori
Japan Nagasaki University Hospital ( Site 0600) Nagasaki
Japan Osaka Medical and Pharmaceutical University Hospital ( Site 0604) Takatsuki Osaka
Japan Tokyo Medical and Dental University Hospital ( Site 0601) Tokyo
Japan Tokyo Metropolitan Komagome Hospital ( Site 0606) Tokyo
Japan University of Tsukuba Hospital ( Site 0605) Tsukuba Ibaraki
Korea, Republic of Chungnam National University Hospital ( Site 0203) Daejeon Taejon-Kwangyokshi
Korea, Republic of National Cancer Center ( Site 0202) Gyeonggi-do Kyonggi-do
Korea, Republic of Seoul National University Bundang Hospital ( Site 0204) Seongnam-si Kyonggi-do
Korea, Republic of Korea University Anam Hospital ( Site 0205) Seoul
Korea, Republic of Severance Hospital Yonsei University Health System ( Site 0201) Seoul
Korea, Republic of Asan Medical Center ( Site 0200) Songpagu Seoul
Latvia Pauls Stradins Clinical University Hospital ( Site 0073) Riga
Malaysia Hospital Kuala Lumpur ( Site 0238) Kuala Lumpur
Malaysia University Malaya Medical Centre ( Site 0236) Kuala Lumpur
Malaysia Hospital Universiti Sains Malaysia ( Site 0237) Kubang Kerian Kelantan
Malaysia Hospital Pulau Pinang ( Site 0239) Penang Pulau Pinang
Netherlands Netherlands Cancer Institute (NKI) ( Site 0183) Amsterdam Noord-Holland
Netherlands Erasmus MC ( Site 0182) Rotterdam Zuid-Holland
Poland Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0152) Koszalin Zachodniopomorskie
Poland Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0153) Krakow Malopolskie
Poland Mazowiecki Szpital Wojewódzki w Siedlcach ( Site 0154) Siedlce Mazowieckie
Portugal Centro Hospitalar e Universitario de Coimbra ( Site 0306) Coimbra
Portugal Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria ( Site 0305) Lisboa
Portugal CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0302) Lisboa
Portugal Hospital Beatriz Angelo ( Site 0303) Loures Lisboa
Puerto Rico Advance Urology and Laparoscopic Center ( Site 0281) Ponce
Puerto Rico PAN American Center Oncologic ( Site 0280) San Juan, Rio Piedras
Romania S.C.Focus Lab Plus S.R.L ( Site 0253) Bucuresti
Romania Institutul Oncologic-Oncologie Medicala ( Site 0256) Cluj
Romania Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249) Cluj Napoca Cluj
Romania S.C. Radiotherapy Center Cluj S.R.L ( Site 0252) Cluj-Napoca Cluj
Romania S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248) Craiova Dolj
Romania Institutul Regional de Oncologie Iasi ( Site 0255) Iasi
Romania Policlinica Oncomed SRL ( Site 0254) Timisoara Timis
Spain Instituto Catalan de Oncologia - ICO ( Site 0103) L Hospitalet De Llobregat Barcelona
Spain HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0106) Sevilla
Spain Hospital La Fe de Valencia ( Site 0105) Valencia Valenciana, Comunitat
Taiwan Kaohsiung Chang Gung Memorial Hospital ( Site 0209) Kaohsiung
Taiwan Taichung Veterans General Hospital ( Site 0213) Taichung
Taiwan National Cheng Kung University Hospital ( Site 0208) Tainan
Taiwan Chi Mei Medical Center ( Site 0215) Tainan City Tainan
Taiwan National Taiwan University Hospital ( Site 0210) Taipei
Taiwan Taipei Veterans General Hospital ( Site 0211) Taipei
Taiwan Chang Gung Medical Foundation.Linkou Branch ( Site 0212) Taoyuan
Turkey Ankara Universitesi Tip Fakultesi. ( Site 0502) Ankara
Turkey University of Health Sciences,Gulhane School of Medicine-Oncology ( Site 0509) Ankara
Turkey Göztepe Prof. Dr. Süleyman Yalçin Sehir Hastanesi-oncology ( Site 0504) Istanbul
Turkey Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 0501) Istanbul
Turkey T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training ( Istanbul
Turkey Ege University Medical Faculty ( Site 0508) Izmir
Turkey Karadeniz Teknik Universitesi Tip Fakultesi ( Site 0503) Trabzon
Ukraine Clinical oncology dispensary of Dnipro ( Site 0133) Dnipro Dnipropetrovska Oblast
Ukraine Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0139) Kharkiv Kharkivska Oblast
Ukraine MNPE Regional Center of Oncology ( Site 0134) Kharkiv Kharkivska Oblast
Ukraine Ukranian Center of TomoTherapy ( Site 0140) Kropyvnytskiy Kirovohradska Oblast
Ukraine Kyiv City Clinical Oncology Center ( Site 0135) Kyiv
Ukraine SNPE National Cancer Institute ( Site 0136) Kyiv Kyivska Oblast
United Kingdom Darlington Memorial Hospital NHS Trust ( Site 0446) Darlington
United Kingdom The Royal Marsden NHS Foundation Trust. ( Site 0442) London London, City Of
United Kingdom University College London Hospitals NHS Foundation Trust ( Site 0445) London London, City Of
United Kingdom Nottingham University Hospital NHS Trust ( Site 0250) Nottingham Nottinghamshire
United Kingdom Royal Preston Hospital ( Site 0449) Preston Lancashire
United Kingdom Betsi Cadwaladr University Health Board ( Site 0447) Rhyl Denbighshire
United Kingdom South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 0444) Torquay Devon
United States New York Oncology Hematology P.C ( Site 0024) Albany New York
United States MidLantic urology ( Site 0070) Bala-Cynwyd Pennsylvania
United States Baltimore VA Medical Center ( Site 0054) Baltimore Maryland
United States Bay Pines VA Medical Center ( Site 0055) Bay Pines Florida
United States Roswell Park Cancer Institute ( Site 6009) Buffalo New York
United States West Virginia University - Charleston Area Medical Center ( Site 6003) Charleston West Virginia
United States Cleveland Clinic Main ( Site 0062) Cleveland Ohio
United States Inova Schar Cancer Institute ( Site 6006) Fairfax Virginia
United States Summit Medical Group Cancer Center ( Site 6008) Florham Park New Jersey
United States Saint Francis Cancer Center ( Site 0026) Greenville South Carolina
United States John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005) Hackensack New Jersey
United States Norton Cancer Institute ( Site 0044) Louisville Kentucky
United States Froedtert and Medical College of Wisconsin ( Site 0022) Milwaukee Wisconsin
United States Winthrop University Hospital ( Site 0069) Mineola New York
United States Carolina Urologic Research Center ( Site 0002) Myrtle Beach South Carolina
United States New York University Perlmutter Cancer Center ( Site 0001) New York New York
United States AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0004) Orlando Florida
United States Pikeville Medical Center ( Site 0009) Pikeville Kentucky
United States Washington University ( Site 0003) Saint Louis Missouri
United States Urology San Antonio Research ( Site 6010) San Antonio Texas
United States Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041) Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Chile,  Czechia,  Denmark,  Estonia,  France,  Guatemala,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Latvia,  Malaysia,  Netherlands,  Poland,  Portugal,  Puerto Rico,  Romania,  Spain,  Taiwan,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bladder Intact Event-Free Survival (BI-EFS) BI-EFS is defined as the time from randomization to any of the following events: residual/recurrent MIBC post-chemoradiotherapy (CRT), nodal or distant metastases as assessed by computerized tomography (CT) and CT urography (CTU) or magnetic resonance urography (MRU) per blinded independent central review (BICR) and/or biopsy results assessed by central pathology review, radical cystectomy, or death due to any cause. If biopsy is not feasible due to participant safety, the imaging alone will be sufficient. The BI-EFS for all participants will be presented. Up to approximately 71 months
Secondary Overall Survival (OS) Time from randomization to death due to any cause. Up to approximately 83 months
Secondary Metastasis-Free Survival (MFS) MFS is defined as the time from randomization to the first documented occurrence of nodal or distant metastases as assessed by CT and CTU or MRU per BICR and/or biopsy results assessed by central pathology review If biopsy is not feasible due to participant safety, the imaging alone will be sufficient. Up to approximately 83 months
Secondary Time to Occurrence of Non-Muscle-Invasive Bladder Cancer (NMIBC) Time to occurrence of low-grade disease, defined as the time from randomization until the development of NMIBC, will be presented. Up to approximately 83 months
Secondary Number of Participants Who Experienced an Adverse Event (AE) An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented. Up to approximately 83 months
Secondary Number of Participants Who Discontinued Study Intervention Due to an AE An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. Up to approximately 1 year
Secondary Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. The change from baseline in Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented. Baseline and up to approximately 83 months
Secondary Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented. Baseline and up to approximately 83 months
Secondary Change from Baseline in Urinary, Bowel, and Sexual Domains of the Bladder Cancer Index (BCI) The BCI is a validated, condition-specific health questionnaire assessing quality of life among participants with bladder cancer. The BCI contains 36 items which assess 3 domains (urinary, bowel, and sexual) with function and bother subdomains. Scores range from 0 to 100 with higher scores corresponding to better functioning and health-related quality of life. The change from baseline in the combined scores of the urinary, bowel, and sexual domains of the BCI will be presented. Baseline and up to approximately 83 months
Secondary Change from Baseline in the Visual Analog Score (VAS) of the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine". The change from baseline in EQ-5D-5L VAS will be presented. Baseline and up to approximately 83 months
Secondary Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30 The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD in Global Health Status/Quality of Life is defined as the time from baseline to the first onset of a 10 point or greater decrease from baseline in the Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score, with or without subsequent confirmation. Up to approximately 83 months
Secondary TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a better quality of life. TTD in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score is defined as the time from baseline (at randomization) to the first onset of a =10-point decrease with confirmation by the subsequent visit of a =10-point decrease in physical functioning Items 1 to 5 scale scores. Up to approximately 83 months
Secondary TTD in Urinary, Bowel, and Sexual Domains of the BCI The BCI is a validated, condition-specific health questionnaire assessing quality of life among participants with bladder cancer. The BCI contains 36 items which assess 3 domains (urinary, bowel, and sexual) with function and bother subdomains. Scores range from 0 to 100 with higher scores corresponding to better functioning and health-related quality of life. TTD in BCI is defined as a 6, 7, and 7 points or greater worsening from baseline for urinary, bowel, and sexual domains, respectively, with or without subsequent confirmation, under a right-censoring rule. Up to approximately 83 months
Secondary TTD in the VAS of the EQ-5D-5L The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine". TTD in EQ-5D-5L VAS is defined as the time from baseline to the first onset of a 7 point or greater decrease from baseline in EQ-5D-5L VAS, with or without subsequent confirmation, under a right-censoring rule. Up to approximately 83 months
Secondary Time to Cystectomy Time to cystectomy is defined as time from a participant's randomization to date of cystectomy. Up to approximately 83 months
See also
  Status Clinical Trial Phase
Terminated NCT02612194 - LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT02805608 - uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer Phase 2
Not yet recruiting NCT02534623 - Postoperative Quality of Recovery After Transurethral Resection of the Bladder N/A
Recruiting NCT02228473 - Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Terminated NCT02560038 - Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer Phase 2
Not yet recruiting NCT02252445 - Propofol and Sevoflurane for Catheter-Related Bladder Discomfort N/A
Not yet recruiting NCT02760953 - TURBt With Adjuvant Cryoablation to Treat Bladder Cancer N/A
Terminated NCT04430036 - AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Phase 2
Active, not recruiting NCT06289283 - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03404791 - A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy Phase 1
Terminated NCT01479348 - Imaging Study for FdCyd and THU Cancer Treatment Early Phase 1
Recruiting NCT05742867 - A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder